Whether peripheral inflammatory molecules can be considered markers of dementia is still an open issue. We have investigated the presence of circulating cytokines and the ability of blood cells to release them in response to an inflammatory stimulus in patients with different types of dementia and in age-matched controls. A significant increase in circulating interleukin-1␤ in moderate Alzheimer and in multiinfarct (145 and 224 times control concentration, respectively) dementia and in circulating tumor necrosis factor-␣ concentration in multiinfarct dementia patient group (156%) were found. Tumor necrosis factor-␣ and interleukin-6 released from blood cells after exposure to lipopolysaccharide were significantly reduced in moderate Alzheimer (60%, both cytokines) and multiinfarct patients (71 and 50%, respectively), while interleukin-10 was decreased only in multiinfarct patients (61%). The results show that patients with Alzheimer disease or multiinfarct dementia have an upregulation of circulating cytokines and a downregulation of cytokines released by blood cells. © 2002 Elsevier Science (USA)
INTRODUCTION
In past years, the possible involvement of inflammation in the pathogenesis of dementia has been the subject of several investigations. Case-control epidemiological studies suggested that the use of anti-inflammatory drugs could reduce the onset and slow the progression of the disease (Akiyama et al., 2000; Lucca, 1999) . In other controlled trials, the anti-inflammatory treatment was ineffective in slowing the rate of cognitive decline of Alzheimer's disease (AD) patients (Aisen et al., 2000) or it was poorly tolerated (Scharf et al., 1999) . However, a recent prospective study conducted on about 7000 subjects reported that long-term use of nonsteroidal anti-inflammatory drugs was associated with a reduction in the risk of AD (in 't Veld et al., 2001) . Thus, the relevance of inflammation in the pathogenesis of this condition seems a consistent hypothesis although the inflammatory mechanisms involved in the pathogenetic cascade are still unknown. Immunohistochemical, biochemical, and molecular studies indicate that a chronic inflammatory reaction is present in selected brain areas of AD patients. In particular, the upregulation of cytokines (Griffin et al., 1998) , chemokines (Xia & Hyman, 1999) , acute phase proteins (Leveugle & Fillit, 1994) , activated complement factors (Yasojima et al., 1999) , and free radicals (Wallace et al., 1997) has been clearly established. These mediators, overproduced by activated microglia (Dickson et al., 1993) and reactive astrocytes (Mrak et al., 1996) , have been reported in the vicinity of ␤-amyloid deposits and neurofibrillary tangles and may play a role in the pathogenesis of the disease (reviewed by McGeer & McGeer, 1999) . Genetic studies indicate that the risk of AD is substantially influenced by a total of 10 polymorphisms in the inflammatory molecules interleukin(IL)-1␣, IL-1␤, IL-6, tumor necrosis fac- 
